CTOs on the Move

Vera Therapeutics

www.veratx.com

 
Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera`s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful, including lupus nephritis, a severe renal manifestation of systemic lupus erythematosus.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.veratx.com
  • 170 Harbor Way 3rd Floor
    South San Francisco, CA USA 94080
  • Phone: 650.770.0077

Executives

Name Title Contact Details
Scott Rossi
 Head of Cybersecurity Profile

Funding

Vera Therapeutics raised $80M on 01/19/2021

Similar Companies

Bristol-Myers Squibb Canada

Bristol-Myers Squibb Canada is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pearl Health Clinic

Pearl Health Clinic provides unparalleled treatment to the community of Eastern Idaho and surrounding areas.

Indicus Pharma

Indicus Pharma is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Adamis Laboratories

Adamis Laboratories, Inc is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enanta

Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).